Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase

Current Opinion in Pharmacology

Volumn 18, Issue , 2014, Pages 76-83

  Ehmann, David E ^a   Lahiri, Sushmita D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AZD 0914; AZD 9742; DNA TOPOISOMERASE INHIBITOR; GATIFLOXACIN; GSK 2140944; GSK 966587; GYRASE INHIBITOR; KIBDELOMYCIN; MOXIFLOXACIN; NATURAL PRODUCT; NBTI 5463; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; DNA TOPOISOMERASE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIOSTASIS; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMING UNIT; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITOR INTERACTION; ENZYME SPECIFICITY; ESCHERICHIA COLI INFECTION; HUMAN; IC50; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; MYOSITIS; NEISSERIACEAE INFECTION; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; PSEUDOMONAS INFECTION; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TUBERCULOSIS; ANIMAL; METABOLISM;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DNA TOPOISOMERASES; TOPOISOMERASE I INHIBITORS; TOPOISOMERASE II INHIBITORS;

EID: 84907581380     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.09.007     Document Type: Review

References (52)

1. K.J. Aldred, R.J. Kerns, and N. Osheroff Mechanism of quinolone action and resistance Biochemistry 53 2014 1565 1574
2. F. Collin, S. Karkare, and A. Maxwell Exploiting bacterial DNA gyrase as a drug target: current state and perspectives Appl Microbiol Biotechnol 92 2011 479 497
3. C. Mayer, and Y.L. Janin Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism Chem Rev 114 2013 2313 2342
4. T. Tomasic, and L.P. Masic Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases Curr Top Med Chem 14 2014 130 151
5. M.K. Kathiravan, M.M. Khilare, K. Nikoomanesh, A.S. Chothe, and K.S. Jain Topoisomerase as target for antibacterial and anticancer drug discovery J Enzyme Inhib Med Chem 28 2013 419 435
6. A. Gubaev, and D. Klostermeier The mechanism of negative DNA supercoiling: a cascade of DNA-induced conformational changes prepares gyrase for strand passage DNA Repair (Amst) 16C 2014 23 34
7. I. Laponogov, D.A. Veselkov, I.M. Crevel, X.S. Pan, L.M. Fisher, and M.R. Sanderson Structure of an 'open' clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport Nucleic Acids Res 41 2013 9911 9923
8. C. Anderle, M. Stieger, M. Burrell, S. Reinelt, A. Maxwell, M. Page, and L. Heide Biological activities of novel gyrase inhibitors of the aminocoumarin class Antimicrob Agents Chemother 52 2008 1982 1990
9. L.W. Tari, X. Li, M. Trzoss, D.C. Bensen, Z. Chen, T. Lam, J. Zhang, S.J. Lee, G. Hough, and D. Phillipson Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents PLOS ONE 8 2013 e84409
10. L.W. Tari, M. Trzoss, D.C. Bensen, X. Li, Z. Chen, T. Lam, J. Zhang, C.J. Creighton, M.L. Cunningham, and B. Kwan Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity Bioorg Med Chem Lett 23 2013 1529 1536
11. M. Trzoss, D.C. Bensen, X. Li, Z. Chen, T. Lam, J. Zhang, C.J. Creighton, M.L. Cunningham, B. Kwan, and M. Stidham Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part II: Development of inhibitors with broad spectrum, Gram-negative antibacterial activity Bioorg Med Chem Lett 23 2013 1537 1543
12. P.R. Tessier, and D.P. Nicolau In vitro activity of novel gyrase inhibitors against a highly resistant population of Pseudomonas aeruginosa Antimicrob Agents Chemother 57 2013 2887 2889
13. G.S. Basarab, J.I. Manchester, S. Bist, P.A. Boriack-Sjodin, B. Dangel, R. Illingworth, B.A. Sherer, S. Sriram, M. Uria-Nickelsen, and A.E. Eakin Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents J Med Chem 56 2013 8712 8735
14. A.E. Eakin, O. Green, N. Hales, G.K. Walkup, S. Bist, A. Singh, G. Mullen, J. Bryant, K. Embrey, and N. Gao Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents Antimicrob Agents Chemother 56 2012 1240 1246
15. B.A. Sherer, K. Hull, O. Green, G. Basarab, S. Hauck, P. Hill, J.T. Loch III, G. Mullen, S. Bist, and J. Bryant Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy Bioorg Med Chem Lett 21 2011 7416 7420
16. M. Uria-Nickelsen, G. Neckermann, S. Sriram, B. Andrews, J.I. Manchester, D. Carcanague, S. Stokes, and K.G. Hull Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines Int J Antimicrob Agents 2013
17. T.H. Grossman, D.J. Bartels, S. Mullin, C.H. Gross, J.D. Parsons, Y. Liao, A. Grillot, D. Stamos, E.R. Olson, P.S. Charifson, and N. Mani Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds Antimicrob Agents Chemother 51 2007 657 666
18. E. Perola, D. Stamos, A.L. Grillot, S. Ronkin, T. Wang, A. Letiran, Q. Tang, D.D. Deininger, Y. Liao, and S.K. Tian Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy Bioorg Med Chem Lett 24 2014 2177 2181
19. J. Finn Evaluation of WO2012177707 and WO2012097269: vertex's phosphate prodrugs of gyrase and topoisomerase antibacterial agents Expert Opin Ther Pat 23 2013 1233 1237
20. S. Jeverica, D. Golparian, B. Hanzelka, A.J. Fowlie, M. Maticic, and M. Unemo High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance J Antimicrob Chemother 69 2014 1866 1872
21. Palmer JT, Lunniss CJ, Offermann DA, Axford LC, Blair M, Mitchell D, Palmer N, Steele C, Atherall J, Watson D et al.: World Patent WO 2012045124; 2012.
22. N.R. Stokes, H.B. Thomaides-Brears, S. Barker, J.M. Bennett, J. Berry, I. Collins, L.G. Czaplewski, V. Gamble, P. Lancett, and A. Logan Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases Antimicrob Agents Chemother 57 2013 5977 5986
23. S.B. Singh, M.A. Goetz, S.K. Smith, D.L. Zink, J. Polishook, R. Onishi, S. Salowe, J. Wiltsie, J. Allocco, and J. Sigmund Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities Bioorg Med Chem Lett 22 2012 7127 7130
24. L. Miesel, D.W. Hecht, J.R. Osmolski, D. Gerding, A. Flattery, F. Li, J. Lan, P. Lipari, J.D. Polishook, and L. Liang Kibdelomycin is a potent and selective agent against toxigenic clostridium difficile Antimicrob Agents Chemother 58 2014 2387 2392
25. P.S. Shirude, P. Madhavapeddi, J.A. Tucker, K. Murugan, V. Patil, H. Basavarajappa, A.V. Raichurkar, V. Humnabadkar, S. Hussein, and S. Sharma Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis ACS Chem Biol 8 2013 519 523
26. S. Karkare, T.T. Chung, F. Collin, L.A. Mitchenall, A.R. McKay, S.J. Greive, J.J. Meyer, N. Lall, and A. Maxwell The naphthoquinone diospyrin is an inhibitor of DNA gyrase with a novel mechanism of action J Biol Chem 288 2013 5149 5156
27. P. SH, S. Solapure, K. Mukherjee, V. Nandi, D. Waterson, R. Shandil, M. Balganesh, V.K. Sambandamurthy, A.K. Raichurkar, and A. Deshpande Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis Antimicrob Agents Chemother 58 2014 61 70
28. S. Chopra, K. Matsuyama, T. Tran, J.P. Malerich, B. Wan, S.G. Franzblau, S. Lun, H. Guo, M.C. Maiga, W.R. Bishai, and P.B. Madrid Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis J Antimicrob Chemother 67 2012 415 421
29. R.R. Kale, M.G. Kale, D. Waterson, A. Raichurkar, S.P. Hameed, M.R. Manjunatha, B.K. Kishore Reddy, K. Malolanarasimhan, V. Shinde, and K. Koushik Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy Bioorg Med Chem Lett 24 2014 870 879
30. M.G. Kale, A. Raichurkar, P. SH, D. Waterson, D. McKinney, M.R. Manjunatha, U. Kranthi, K. Koushik, L. Jena, and V. Shinde Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B J Med Chem 56 2013 8834 8848
31. C. d'Urso de Souza Mendes, and A. Maria de Souza Antunes Pipeline of known chemical classes of antibiotics Antibiotics 2 2013 500
32. B.D. Bax, P.F. Chan, D.S. Eggleston, A. Fosberry, D.R. Gentry, F. Gorrec, I. Giordano, M.M. Hann, A. Hennessy, and M. Hibbs Type IIA topoisomerase inhibition by a new class of antibacterial agents Nature 466 2010 935 940
33. M.T. Black, and K. Coleman New inhibitors of bacterial topoisomerase GyrA/ParC subunits Curr Opin Investig Drugs 10 2009 804 810
34. F. Reck, R. Alm, P. Brassil, J. Newman, B. de Jonge, C.J. Eyermann, G. Breault, J. Breen, J. Comita-Prevoir, and M. Cronin Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity J Med Chem 54 2011 7834 7847
35. T.J. Miles, A.J. Hennessy, B. Bax, G. Brooks, B.S. Brown, P. Brown, N. Cailleau, D. Chen, S. Dabbs, and D.T. Davies Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases Bioorg Med Chem Lett 23 2013 5437 5441
36. S.K. Bouchillon, M. Hackel, L.A. Miller, and N.E. Scangarella-Oman Abstract F-1216 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September, Denver, CO 2013
37. C.A. Tiffany, M. Hossain, M. McDonald, A. Patel, S. Lerman, P. Patel, K. Widdowson, and E. Dumont Abstract F-1218 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September, Denver, CO 2013
38. ClinicalTrials.gov website; http://clinicaltrials.gov.
39. D.J. Payne Presentation 142, American Society of Microbiology, Biodefense and Emerging Diseases Research Meeting January, Washington DC 2014
40. F. Reck, R.A. Alm, P. Brassil, J.V. Newman, P. Ciaccio, J. McNulty, H. Barthlow, K. Goteti, J. Breen, and J. Comita-Prevoir Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile J Med Chem 55 2012 6916 6933
41. T.J. Dougherty, A. Nayar, J.V. Newman, S. Hopkins, G.G. Stone, M. Johnstone, A.B. Shapiro, M. Cronin, F. Reck, and D.E. Ehmann NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy Antimicrob Agents Chemother 58 2014 2657 2664
42. S.B. Singh, D.E. Kaelin, J. Wu, L. Miesel, C.M. Tan, P.T. Meinke, D. Olsen, A. Lagrutta, P. Bradley, and J. Lu Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents ACS Med Chem Lett 5 2014 609 614
43. M.J. Mitton-Fry, S.J. Brickner, J.C. Hamel, L. Brennan, J.M. Casavant, M. Chen, T. Chen, X. Ding, J. Driscoll, and J. Hardink Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV Bioorg Med Chem Lett 23 2013 2955 2961
44. J.P. Surivet, C. Zumbrunn, G. Rueedi, C. Hubschwerlen, D. Bur, T. Bruyere, H. Locher, D. Ritz, W. Keck, and P. Seiler Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity J Med Chem 56 2013 7396 7415
45. A.A. Miller, G.L. Bundy, J.E. Mott, J.E. Skepner, T.P. Boyle, D.W. Harris, A.E. Hromockyj, K.R. Marotti, G.E. Zurenko, and J.B. Munzner Discovery and Characterization of QPT-1, the Progenitor of A New Class of Bacterial Topoisomerase Inhibitors Antimicrob Agents Chemother 52 2008 2806 2812
46. M.D. Huband, R.K. Flamm, P.R. Rhomberg, J.P. Mueller, and R.N. Jones Abstract F-1225b 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September, Denver, CO 2013
47. J.V. Newman, W. Luo, K. Farrington, V.J.A. Schuck, M.A. Tanudra, M.E. Beaudoin, R. Singh, and J.P. Mueller Abstract F-1225a 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September, Denver, CO 2013
48. V.J.A. Schuck, K. Vishwanathan, J.V. Newman, M.D. Huband, G. Kern, G. Basarab, and J.P. Mueller Abstract F-1225d 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September, Denver, CO 2013
49. F. Collin, R.E. Thompson, K.A. Jolliffe, R.J. Payne, and A. Maxwell Fragments of the bacterial toxin microcin B17 as gyrase poisons PLoS ONE 8 2013 e61459
50. M.H. Foss, K.A. Hurley, N. Sorto, L.L. Lackner, K.M. Thornton, J.T. Shaw, and D.B. Weibel N-Benzyl-3-sulfonamidopyrrolidines are a new class of bacterial DNA gyrase inhibitors ACS Med Chem Lett 2 2011 289 292
51. M. Rajendram, K.A. Hurley, M.H. Foss, K.M. Thornton, J.T. Moore, J.T. Shaw, and D.B. Weibel Gyramides prevent bacterial growth by inhibiting DNA gyrase and altering chromosome topology ACS Chem Biol 9 2014 1312 1319
52. F. Duan, X. Li, S. Cai, G. Xin, Y. Wang, D. Du, S. He, B. Huang, X. Guo, and H. Zhao Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase I J Med Chem 57 2014 3707 3714